Published in Vaccine Weekly, October 25th, 1999
These novel recombinant chimeric virus-like particles (VLP) are non-infectious vaccine candidates designed to either treat or prevent HPV infections that cause genital warts and cervical cancer. These HPV vaccines were developed by research and development teams lead by Robin Robinson, PhD, NBSD, and Douglas Lowy, MD of the Laboratory of Cellular Oncology at the National Cancer Institute in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly